

Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States



Zheming Yu^{1,2}, Hamed Samavat³, Allison M. Dostal⁴, Renwei Wang¹, Carolyn J. Torkelson⁵, Chung S. Yang⁶, Lesley M. Butler^{1,2}, Thomas W. Kensler^{1,7}, Anna H. Wu⁸, Mindy S. Kurzer³, and Jian-Min Yuan^{1,2}

Abstract

Liver injury effects of green tea-based products have been reported in sporadic case reports. However, no study has examined systematically such adverse effects in an unbiased manner. We examined the potential effects of a high, sustained oral dose of green tea extract (GTE) on liver injury measures in a randomized, placebo-controlled, double-blinded phase II clinical trial, which enrolled 1,075 women with the original aim to assess the effect of daily GTE consumption for 12 months on biomarkers of breast cancer risk. The current analysis examined the effect of GTE consumption on liver injury in 1,021 participants (513 in GTE and 508 in placebo arm) with normal baseline levels of liver enzymes. Among women in the GTE arm, alanine aminotransferase (ALT) increased by 5.4 U/L [95% confidence interval (CI),

3.6–7.1] and aspartate aminotransferase increased by 3.8 U/L (95% CI, 2.5–5.1), which were significantly higher than those among women in the placebo arm (both $P < 0.001$). Overall, 26 (5.1%) women in GTE developed moderate or more severe abnormalities in any liver function measure during the intervention period, yielding an OR of 7.0 (95% CI, 2.4–20.3) for developing liver function abnormalities as compared with those in the placebo arm. ALT returned to normal after dechallenge and increased again after one or more rechallenges with GTE. The rise-fall pattern of liver enzyme values following the challenge-dechallenge cycles of GTE consumption strongly implicates the effect of high-dose GTE on liver enzyme elevations. *Cancer Prev Res; 10(10); 571–9. ©2017 AACR.*

Introduction

Tea, obtained from the plant *Camellia sinensis*, is the second most popular beverage in the world. Several types of tea are produced by different postharvest processing methods. Green tea is a product of fresh tea leaves that are heated or steamed, rolled, and dried with minimal enzymatic oxidation after harvest. Water-extractable components from green tea contain about 30%–40%

tea catechins in dry weight, with (–)-epigallocatechin-3-gallate (EGCG) comprising on average two-thirds of total tea catechins (1). Extensive *in vitro* and animal studies have consistently shown the inhibitory activities of green tea extract (GTE) and green tea catechins, especially EGCG, against tumorigenesis at different organ sites (2). Epidemiologic studies suggest that drinking green tea offers some protection against the risk of several cancers including liver cancer (3–5). Tea consumption has also been associated with reduced mortality due to cardiovascular disease, body weight reduction, and metabolic syndrome alleviation (6, 7).

The potential health benefits associated with the consumption of GTE and other green tea products have been attributed partially to the antioxidant and other properties of catechins, especially EGCG (8). However, EGCG at high doses has been shown to induce hepatotoxicity in animal models (9, 10). More than 50 case reports on hepatic adverse events associated with the consumption of high-dose green tea-herbal products have been described during the past 15 years, 19 of them with GTE as the major constituents (11, 12). Recently, we found that among participants with positive serology of hepatitis B surface-antigen (HBsAg), urinary excretion of epigallocatechin (EGC) at levels equivalent to five cups of green tea per day was associated with a significant two-fold increased risk of hepatocellular carcinoma compared with undetectable EGC in the Shanghai Cohort Study (13).

Despite the inconsistent results between the potential protective effect of drinking green tea on liver cancer observed in epidemiologic studies, and hepatic adverse effect of high-dose green tea-containing herbal supplements in case reports, there

¹University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. ²Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. ³Department of Food Science & Nutrition, University of Minnesota, St. Paul, Minnesota. ⁴Department of Medicine, Division of Gastroenterology, Hepatology, & Nutrition, University of Minnesota, Minneapolis, Minnesota. ⁵Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, Minnesota. ⁶Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey. ⁷Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. ⁸Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California.

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

clinicaltrials.gov Identifier: NCT00917735

Corresponding Author: Jian-Min Yuan, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Suite 4C, 5150 Centre Avenue, Pittsburgh, PA 15232. Phone: 412-864-7889; Fax: 412-623-3303; E-mail: yuanj@upmc.edu

doi: 10.1158/1940-6207.CAPR-17-0160

©2017 American Association for Cancer Research.

have been no data from randomized clinical trials with large sample size and long-term treatment with a high dose of GTE (i.e., higher than 500 mg EGCG, equivalent to three 240-mL servings of green tea per day) on measures of liver injury in humans (6, 14). In the Minnesota Green Tea Trial (MGTT), a higher proportion of women in the treatment than the placebo arm developed gastrointestinal-related adverse events, including liver function measures (15). Utilizing this dataset (16), we conducted a detailed analysis to determine the time course and the possible effects of a high, sustained dose of encapsulated GTE on liver injury. In addition, we evaluated the potential modifying effects of lifestyle factors and concurrent use of medications on the association between GTE consumption and liver injury.

Materials and Methods

Participants

The design of the MGTT has been described in detail previously (16). In brief, the MGTT was a randomized, double-blinded, placebo-controlled phase II clinical trial designed to investigate the effects of oral intake of a high dose of GTE as a dietary supplement on biomarkers of breast cancer risk. Postmenopausal women ages 50–70 years with heterogeneously dense (51%–75% glandular) or extremely dense (>75% glandular) breasts otherwise in good health were eligible. Participants were excluded before randomization if they tested serologic positive for either hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus (HCV), which indicate chronic infection with hepatitis B or C virus, respectively; had elevated liver enzyme alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal (ULN); were diagnosed with diabetes mellitus, or any other lifestyle factors (alcohol drinking and cigarette smoking) that may influence metabolism of sex hormones and oxidative stress outcomes. The study enrolled 1,075 women from 2009 to 2013 in the Minneapolis-St. Paul metropolitan area; 538 were randomly assigned to the GTE and 537 to the placebo group. At the baseline visit, each participant completed a self-administered questionnaire requesting information on demographics, smoking and alcohol use, medical history, medication use, and dietary intake during the past 12 months. Body weight, height, and waist and hip circumferences were measured at the research clinic. Blood samples were collected at baseline and in clinical visits during the 12-month intervention period for monitoring liver function.

This current analysis on the liver injury effect of GTE was restricted to 1,021 participants (513 in the GTE and 508 in the placebo arm) with normal baseline serum ALT (≤ 75 U/L). We excluded: (i) three participants (all in the GTE arm) with missing baseline values; and (ii) 51 participants (22 in the GTE and 29 in the placebo group) who withdrew from the study before the first monthly liver panel test was conducted (Fig. 1).

Supplementation with GTEs

The original source of green tea was from the Youshan Tea Farm in China. The compounds were extracted from dried green tea leaves with water and ethyl acetate, decaffeinated and spray-dried in the Taiyo Green Power Co. Ltd. The extracted compounds were imported to the U.S. by Taiyo International Inc., and were encapsulated by Corban Laboratories/Eniva Nutraceuticals.

GTE and placebo capsules were identical in appearance and were produced and provided by Corban Laboratories. The cate-

chin contents of all eight batches of GTE were quantified using high-performance liquid chromatography technology at Covance Laboratories, and confirmed in the laboratory of C.S. Yang. Mean (SD) of specific catechins per GTE capsule was 328.8 (28.9) mg total catechins that included 210.7 (11.0) mg EGCG, 50.6 (18.5) mg epicatechin gallate (ECG), 26.7 (29.7) mg EGC, and 26.8 (5.9) mg epicatechin (EC). Each GTE capsule also contained 3.9 mg caffeine. Each placebo capsule contained 204 mg maltodextrin (50%), 202 mg cellulose (49.5%), and 2 mg magnesium stearate (0.5%), but did not contain any tea catechins or caffeine. GTE and placebo capsules were stored at ambient temperature (20–25°C) in 40% to 45% humidity prior to dispensing to study participants by the investigational drug services pharmacy at the University of Minnesota.

Participants were blinded to treatment assignment and were instructed to take two capsules at breakfast and two capsules at dinner daily for 12 months. The mean daily dose (SD) of tea catechins was 1,315 (115.4) mg total catechins including 843 (44.1) mg EGCG, 202 (74.0) mg ECG, 106 (118.8) mg EGC, 107 (23.4) mg EC, and 15.8 mg caffeine. The amount of EGCG was equivalent to approximately five cups (equivalent to 8 fluid ounces or 240 mL) of brewed green tea per day (17).


Liver injury measure

The hepatic panel, including ALT, aspartate aminotransferase (AST), alkaline phosphatase (AKP), albumin globulin, total proteins, albumin/globulin ratio, and indirect, direct, and total bilirubin were tested in serum collected from study participants at baseline and in follow-up clinical visits (Quest Diagnostics). The original protocol requested a monthly blood draw, which was changed to months 1, 2, 3, 4, 5, 6, 9, and 12 for participants enrolled after first 2 years given that ALT elevation was rare after it had been normal in the first 6 months of monitoring.

Because our study participants were healthy postmenopausal women, the liver injury grading system developed by the Acquired Immune Deficiency Syndrome Clinical Trials Group was used for this analysis (18). Based on the highest value of four liver function measures during the entire 12-month intervention period, individuals were classified as grade 0 or no abnormal liver function if all three liver enzymes were $< 1.25 \times$ ULN (ULN: ALT = 60, AST = 35, AKP = 135 U/L) and total bilirubin $\leq 1 \times$ ULN (ULN: ≤ 1.2 mg/dL), grade 1 abnormal liver function if any liver enzyme was 1.25 to $2.5 \times$ ULN or total bilirubin > 1 to $1.5 \times$ ULN, grade 2 (mild) abnormal liver function if any liver enzyme was > 2.5 to $5.0 \times$ ULN or total bilirubin > 1.5 to $2.5 \times$ ULN, grade 3 (moderate) abnormal liver function if any liver enzyme was > 5 to $10 \times$ ULN or total bilirubin > 2.5 to $5 \times$ ULN, or grade 4 (severe) abnormal liver function if any liver enzyme was $> 10 \times$ ULN or total bilirubin $> 5 \times$ ULN (Supplementary Table S1). Liver injury would be considered if patient had jaundice or signs of hepatic or organ failure or hospitalized.

According to the protocol of this primary intervention study, any ALT value above 1.5 times ULN (> 90 U/L) during the treatment period, a predefined adverse event, triggered the change of treatment course and required participants to stop taking study capsules immediately. The repeated liver function tests (LFT) were conducted once every 2 weeks for all those participants until their ALT returned to below $1.5 \times$ ULN (≤ 90 U/L). If the peak

Figure 1. Flow diagram of participant screening, enrollment, randomization, and eligible for the present sub-study, the Minnesota Green Trial, 2009 to 2015 (16).



ALT value was $\leq 5 \times \text{ULN}$ ($\leq 300 \text{ U/L}$), the participant was requested to resume intake of study capsules. If the peak ALT value was $> 5 \times \text{ULN}$, the participant was permanently withdrawn from the study, but follow-up continued to the end of planned intervention period.

Statistical analysis

The distributions of demographic characteristics at baseline [age, race, education, body mass index (BMI), smoking and alcohol status], dietary nutrients, use of medication, and serum concentrations of lipids were compared between participants in the GTE and in the placebo groups. Differences were examined by Student *t* (for continuous variables) or χ^2 test (for categorical variables).

Changes in levels of serum ALT, AST, AKP, and total bilirubin from baseline to the peak value observed during the entire intervention period were compared between the GTE and placebo groups using a generalized linear mixed effect model with adjustment for age, education, BMI, and smoking status (never vs. former smokers) at baseline. The effects of obesity, alcohol use and other potential modifiers on ALT and AST during the course of intervention were examined using the same regression model.

The unconditional logistic regression method was employed to calculate the ORs and their 95% confidence intervals (CI) for overall and different grades of abnormal liver function measures associated with the intake of GTE. Potential confounding variables were adjusted.

Table 1. Distributions of characteristics at baseline among study participants in the GTE and placebo group, The Minnesota Green Tea Trial, 2009–2015

Characteristics	Placebo	GTE	P ^a
No. of total participants, <i>n</i> (%)	508 (100) ^b	513 (100) ^b	
Age at baseline (year), mean (SD)	59.6 (5.0)	59.9 (5.0)	0.32
Caucasian race, <i>n</i> (%)	491 (97.2)	501 (98.0)	0.39
Level of education, <i>n</i> (%)			0.13
High school or below	37 (7.3)	30 (5.9)	
Some college	84 (16.7)	110 (21.5)	
College graduate	221 (43.9)	229 (44.8)	
Postgraduate/professional degree	162 (32.1)	142 (27.8)	
Body mass index (kg/m ²), mean (SD)	25.1 (3.8)	25.2 (3.7)	0.79
<30, <i>n</i> (%)	459 (90.4)	447 (87.1)	0.10
≥30, <i>n</i> (%)	49 (9.7)	66 (12.9)	
Former smokers, <i>n</i> (%)	146 (31.7)	149 (32.6)	0.78
No. years of quitting smoking, mean (SD)	26.2 (11.3)	25.8 (10.2)	0.52
Current use of alcohol (<7 drinks/week), <i>n</i> (%)	426 (84.2)	410 (79.9)	0.08
No. of drinks per week, mean (SD)	3.4 (3.0)	3.3 (3.0)	0.92
Use of medication, <i>n</i> (%)			
Acetaminophen	137 (27.0)	150 (29.3)	0.42
Aspirin	140 (27.6)	136 (26.6)	0.71
Non-aspirin NSAIDs	338 (66.7)	354 (69.1)	0.40
Statin	106 (20.9)	115 (22.5)	0.55
Total cholesterol (mg/dL), mean (SD)	209.3 (31.5)	206.5 (30.6)	0.22
<200, <i>n</i> (%)	189 (40.0)	197 (42.8)	0.63
200–240, <i>n</i> (%)	212 (44.8)	200 (43.5)	
>240, <i>n</i> (%)	72 (15.2)	63 (13.7)	
Total triglyceride (mg/dL), mean (SD)	101.8 (48.5)	93.5 (43.2)	0.01
<150, <i>n</i> (%)	409 (86.5)	414 (90.0)	0.09
≥150, <i>n</i> (%)	64 (13.5)	46 (10.0)	

^aTwo-sided *P* values were derived from *t* test (for continuous variables) or χ^2 test (for categorical or nominal variables).

^bThe sum of some variables may be less than the total due to missing values.

Statistical computing was conducted using SAS version 9.4 (SAS Inc.). All *P* values were two-sided. *P* values < 0.05 were considered to be statistically significant.

Results

All baseline characteristics of study participants in the two treatment groups were comparable except for serum total triglyceride concentration, which was lower in the GTE than in the placebo arm (*P* = 0.01; Table 1). At baseline, women using statins had statistically significant higher levels of serum ALT. In the placebo arm, weekly drinkers of alcoholic beverages had lower levels of serum AST compared with nondrinkers, and women with BMI ≥30 kg/m² had higher level of serum ALT compared with women with BMI <30 kg/m². Other characteristics did not have significant effects on either ALT or AST concentrations (Supplementary Table S2).

The mean levels of ALT, AKP, and total bilirubin at baseline were comparable between the GTE and placebo arms, whereas the baseline AST mean in the placebo was slightly higher than in the GTE arm. GTE intake significantly increased both ALT and AST during the treatment period from baseline levels. These changes were significantly greater than the same enzyme changes in the placebo arm (both *P* < 0.001). On the contrary, such changes of AKP and total bilirubin were not statistically significant between GTE and placebo arms (Table 2).

Among 513 women with normal baseline ALT in the GTE arm, 44 (8.6%) had elevated ALT above 1.25 × ULN compared with 9 (1.8%) of 508 women in the placebo arm; yielding an OR of 5.1 (95% CI, 2.5–10.7). Furthermore, 17 (3.3%) women in the GTE but none in the placebo developed moderate or severe liver enzyme elevation (ALT >2.5 × ULN; Table 3). Among these 17

women, five had moderate (>5–10 × ULN ALT) and three had severe liver enzyme elevation (>10 × ULN ALT). We further explored if subjects with elevated ALT (*n* = 44) had different characteristics at baseline than those with normal ALT with GTE supplement (*n* = 469). We did not detect any statistically significant difference in age, race, education, BMI, use of alcohol, history of smoking, use of aspirin, other NSAIDs or acetaminophen, and use of statin. The baseline mean levels of total cholesterol, total triglyceride, AKP, and total bilirubin were comparable between these two groups (Supplementary Table S3). Although all baseline ALT were within normal range, subjects whose ALT increased above 1.25 × ULN during the GTE treatment period had slightly higher baseline ALT mean = 20.8, SD = 9.7 U/L, compared to subjects with consistently normal ALT (mean = 17.3, SD = 6.3 U/L).

Similar to ALT, AST level increased in 66 (12.8%) women in the GTE and 22 (4.3%) women in the placebo during the intervention period (OR = 3.4; 95% CI, 2.0–5.5; Table 3). AST was highly correlated with ALT. After excluding participants with >1.25 × ULN ALT, 24 women in the GTE and 14 women in the placebo had abnormal AST elevation (OR = 2.0; 95% CI, 1.0–3.9; data not shown). GTE intake had no effect on AKP and total bilirubin (Table 3). When the four measures for drug-induced liver function abnormalities were considered together, 26 participants in the GTE arm and four in the placebo arm had one or more moderate liver enzyme elevations, yielding an OR of 7.0 (95% CI, 2.4–20.3). The participants (23 in the GTE arm and 21 in the placebo arm) with baseline LFTs results greater than ULN defined in Supplementary Table S1 did not show a differential effect of GTE on ALT elevation level during the intervention period (*P*_{interaction} = 0.41; Supplementary Table S4).

Table 2. Change of serum liver functional tests during the intervention period from baseline in all participants, the Minnesota Green Tea Trial, 2009 to 2015

	Placebo	GTE	P
No. of participants	508	513	
ALT (U/L)			
Mean (95% CI) at baseline	18.0 (17.5–18.7)	17.6 (17.0–18.7)	0.25
Mean change (95% CI) from baseline	–0.5 (–2.2–1.3)	5.4 (3.6–7.1)	<0.001 ^a
AST (U/L)			
Mean (95% CI) at baseline	20.7 (20.2–21.2)	20.0 (19.6–20.4)	0.04
Mean change (95% CI) from baseline	–0.2 (–1.5–1.1)	3.8 (2.5–5.1)	<0.001 ^a
AKP (U/L)			
Mean (95% CI) at baseline	69.8 (68.2–71.3)	69.1 (67.4–70.8)	0.29
Mean change (95% CI) from baseline	0.8 (–0.6–2.1)	0.2 (–1.1–1.5)	0.19 ^a
Total bilirubin (mg/dL)			
Mean (95% CI) at baseline	0.51 (0.49–0.53)	0.50 (0.48–0.52)	0.32
Mean change (95% CI) from baseline	0.02 (–0.001–0.04)	0.02 (–0.001–0.04)	0.95 ^a

^aTwo-sided *P* values were derived from generalized linear mixed models comparing the changes of liver functional tests during the intervention period from baseline among women in the GTE group to the corresponding changes in the placebo group after adjustments for age, level of education, body mass index, and smoking status.

The effect of GTE intake on ALT and AST elevation was stronger in obese women, but less in weekly alcohol drinkers (Table 4). The impact of GTE on ALT increase was less in current users of non-aspirin NSAID than nonusers ($P_{\text{interaction}} = 0.003$), whereas serum concentrations of triglycerides or cholesterol, or use of aspirin, acetaminophen, and statin were not associated with the differential effect of GTE on the changes of ALT or AST (Supplementary Table S5).

During the intervention period, ALT concentrations increased above 90 U/L for 36 women in the GTE and 4 women in the placebo arm, the predetermined level that required the change of treatment course (Supplementary Table S6). Among these

women, the median time interval from initial GTE intake to the first detected ALT ≥ 90 U/L was 106 days (range: 56–365 days). The mean peak value of ALT was 238 U/L (range: 93–2,055 U/L), approximately 12 times the mean value of ALT at baseline. ALT returned to <90 U/L after a mean of 32 days (range: 13–92 days) of discontinuing intake of GTE capsules for all 36 women. Twenty women resumed GTE intake after their ALT returned to <90 U/L. Among them, 9 (45%) showed ALT below 90 U/L for the rest of the treatment period whereas 11 (55%) had ALT increased above 90 U/L again. There were eight individuals whose ALT increased about $5 \times$ ULN (>300 U/L), a severe ALT elevation, however none of them reported liver injury symptoms and signs such as jaundice or liver failure (Supplementary Table S7).

ALT concentrations increased and decreased following the GTE challenge/dechallenge pattern. Overall, 17 women—all in the GTE arm—had ALT above $2.5 \times$ ULN (moderate or more severe liver enzyme elevations) during the course of intervention (Fig. 2 and Supplementary Table S6). Six of the 17 resumed GTE intake after their ALT fell below 90 U/L; all six ALT increased above 90 U/L again after resuming GTE intake for 58 (23–114) days and returned to below 90 U/L after discontinuing GTE intake for 30 (16–43) days. Three women (IDs: G26, G27, G32) resumed GTE intake for a third time; ALT increased above 90 U/L after resuming GTE intake for 38 (32–46) days for all three participants and returned to below 90 U/L after discontinuing intake of GTE capsules for 21 (16–32) days for a third time (Fig. 2B).

Discussion

This analysis demonstrates that sustained consumption of a high daily dose of GTE as a dietary supplement (approximately 1,300 mg total tea catechins, 800 mg EGCG) may relate with mild to severe liver enzyme elevation in a small percentage (5.1%) of healthy postmenopausal women who were negative for both HBsAg and anti-HCV in serum at baseline and had reported no history of chronic liver disease, current tobacco use, or consumption of >7 alcoholic beverages weekly. Compared with women in the placebo group, participants randomized to receive GTE capsules were approximately seven times more likely to develop mild or more severe (i.e., grade 2 or higher) liver enzyme elevation. The induction period from the initial intake to the manifestation of mild or more severe liver enzyme elevation varied widely among different participants, from a

Table 3. OR of developing abnormal liver functional tests for women assigned to the GTE versus placebo group during the 12-month treatment period, the Minnesota Green Tea Trial, 2009 to 2015

	Placebo	GTE	OR (95% CI) ^a
ALT			
Normal (<75 U/L)	499	469	1.0
Abnormal (≥ 75 U/L) ^b	9	44	5.1 (2.5–10.7)
Grade 1 (75–150 U/L)	9	27	3.2 (1.5–6.8)
Grade 2 or above (>150 U/L)	0	17	25.5 (5.5, N/A) ^c
AST			
Normal (<43.75 U/L)	486	447	1.0
Abnormal (≥ 43.75 U/L) ^b	22	66	3.4 (2.0–5.5)
Grade 1 (43.75–87.5 U/L)	21	40	2.1 (1.2–3.7)
Grade 2 or above (>87.5 U/L)	1	26	28.6 (3.9–212.5)
AKP			
Normal (<162.5 U/L)	507	508	1.0
Abnormal (≥ 162.5 U/L) ^{b,d}	1	5	4.2 (0.5–36.7)
Total bilirubin			
Normal (≤ 1.20 mg/dL)	483	492	1.0
Abnormal (>1.20 mg/dL)	25	21	0.8 (0.5–1.5)
Grade 1 (1.20–1.80 mg/dL)	22	20	0.9 (0.5–1.7)
Grade 2 (>1.8 mg/dL)	3	1	0.3 (0.03–1.4)
Summed liver injury measure			
All normal ^e	459	428	1.0
Any abnormal	49	85	1.8 (1.3–2.7)
Grade 1	45	59	1.4 (0.9–2.1)
Grade 2 or above	4	26	7.0 (2.4–20.3)

^aOR were derived from unconditional logistic regression models that also included age, BMI, smoking status, and level of education.

^bAbnormal hepatic aminotransferases was defined as having at least one elevation above ULN during the monthly LFTs after randomization.

^cOR was derived from exact logistic regression model, and upper confidence interval was not estimated.

^dNo participants in grade 2 or above.

^eAll of LFTs are in grade 0.

Table 4. Change of serum ALT and AST during the intervention period from baseline in subgroups stratified by selected baseline characteristics, the Minnesota Green Tea Trial, 2009 to 2015

	Placebo		GTE		<i>P</i> ^b	<i>P</i> _{int} ^c
	No.	Mean (95% CI) ^a	No.	Mean (95% CI) ^a		
Mean changes in ALT (U/L) from baseline						
BMI (kg/m ²)						0.08
<25	278	-0.6 (-2.3-1.2)	282	5.1 (3.2-6.9)	<0.0001	
25-30	181	-0.3 (-2.2-1.6)	165	5.0 (3.1-6.9)	<0.0001	
≥30	49	-0.8 (-3.2-1.6)	66	7.5 (5.3-9.8)	<0.0001	
<i>P</i> ^d		0.54		0.005		
Current alcohol drinker						
No	80	-1.2 (-3.3-0.9)	103	7.2 (4.2-9.3)	<0.0001	0.002
Yes	426	-0.3 (-2.0-1.5)	410	5.0 (3.2-6.8)	<0.0001	
<i>P</i> ^d		0.22		0.002		
Mean changes in AST (U/L) from baseline						
BMI (kg/m ²)						0.15
<25	278	0.001 (-1.4-1.4)	282	3.7 (2.4-5.1)	<0.0001	
25-30	181	-0.3 (-1.7-1.1)	165	3.4 (2.4-5.1)	<0.0001	
≥30	49	-0.5 (-2.3-1.3)	66	5.1 (3.4-6.8)	<0.0001	
<i>P</i> ^d		0.70		0.04		
Current alcohol drinker						
No	80	-1.0 (-2.6-0.6)	103	5.5 (3.9-7.1)	<0.0001	<0.001
Yes	426	0.1 (-1.2-1.4)	410	3.5 (2.1-4.8)	<0.0001	
<i>P</i> ^d		0.07		0.0001		

COMT, catechol-O-methyltransferase. All means are from least squares means.

^aTwo-sided *P* values were derived from generalized linear mixed models comparing the changes of liver enzyme (ALT or AST) during the intervention period from baseline of women in the GTE group to the corresponding changes in the placebo group after adjustments for age, BMI, smoking status, and level of education.

^bTwo-sided *P* values were derived from the same model assessing the interaction between the intervention (GTE or placebo) and the stratifying variables on the liver enzyme (ALT or AST) with the same adjustments.

^cTwo-sided *P* values were derived from the same model comparing the differences in changes of liver enzyme (ALT or AST) from baseline among different levels of stratifying variables within the GTE or placebo group.

minimum of 2 months to a maximum of 1 year. Abnormal LFTs induced by GTE were transient; ALT levels returned to below 1.5 times ULN on average within about 1 month after cessation of GTE intake. Among women who experienced initial liver enzyme elevation (i.e., ALT ≥90 U/L), more than half of women who resumed GTE intake a second time according to the study protocol and all the women who resumed GTE intake a third time experienced elevated ALT above 1.5 times ULN again. The rise-fall pattern of serum liver enzyme levels following the dechallenge-rechallenge cycles of GTE treatment strongly implicates a possible association of this high-dose GTE capsule regimen on liver laboratory abnormalities in a subset of postmenopausal women who are sensitive to GTE. Green tea-based products are the fifth most commonly consumed dietary supplement in the United States (19). Some brands of green tea supplements contain as much as 1,350 mg tea catechins in a single tablet. The public should be aware of the potential liver injury from consumption of high-dose green tea-based products.

Our findings are based on a well-designed and carefully implemented randomized, double-blinded, placebo-controlled phase II clinical trial of GTE in a large population of healthy U.S. women. These unequivocal results ruled out possibilities of confounding effects inherent in previous case reports on the liver injury of green tea-based products (11, 12). All study participants had normal baseline liver function panels, had no infection with hepatitis B or C virus or history of liver disease. Both GTE and placebo capsules were produced by the same GMP-certified facility with high standard of quality control. The contents of both GTE and placebo capsules were well characterized and quantified. In addition, compliance was monitored rigorously (16). Thus, the liver enzyme elevations are easily interpretable and attributable to GTE.

The biological mechanism whereby GTE provokes liver injury is not well-understood. *In vitro* and *in vivo* animal experiments support the pro-oxidant property of tea catechins; EGCG facilitates generation of reactive oxygen species (ROS), depletion of glutathione, and collapse of the mitochondrial membrane potential of hepatocytes (20). Excess production of ROS may alter intracellular proteins, increase cell membrane permeability, and induce apoptosis (21). It has been demonstrated that glutathione-depleted cells are susceptible to oxidation and further cell damage (22). EGCG-related ROS formation occurs biphasically, that is, at low doses EGCG decreases ROS production whereas at high doses EGCG increases ROS generation and damages the mitochondrial membrane of hepatocytes (23). Mice given an oral dose of 1,500 mg/kg EGCG showed 8- to 108-fold increases in serum ALT levels after 24 and 48 hours as compared to the control group, along with increased oxidative stress damage, hepatic necrosis, and increased plasma IL6 (9).

Obesity and its complications, including dyslipidemia, inflammation, and oxidative stress, are strong metabolic risk factors for fatty liver disease (24, 25). In one longitudinal study in a Mexican population, weight gain increased ALT levels by more than three times (26). The high prevalence of obesity in the United States has led to high incidence of nonalcoholic fatty liver disease and chronic liver disease (27). Green tea-based products are widely used as a dietary supplement for weight loss (28-30). However, high doses of tea catechins may enhance liver injury, especially for obese individuals along with oxidative stress (9, 31). As shown in Table 4, the interaction term between BMI and GTE intake was borderline statistically significant; the change in ALT by GTE was greater in women with BMI ≥30 kg/m² than women with BMI <30 kg/m² (*P*_{interaction} = 0.08), suggesting that obesity may exacerbate




Figure 2.

Levels of serum ALT in participants whose ALT increased above 150 U/L ($2.5 \times$ ULN) over the course of treatment period. **A**, Participants in the GTE arm with a single ALT peak >150 U/L. **B**, Participants in the GTE arm with at least one ALT peak >150 U/L and underwent one or more dechallenge-rechallenge cycles of GTE treatment; solid line denotes the period for GTE consumption and dashed line denotes the period for withdrawal from consumption.

the adverse effect of high-dose GTE on the liver enzyme elevation. However, it should be noted that the effects of GTE on ALT elevation in women with BMI <25 and 25 to <30 kg/m^2 were statistically significant.

This study, similar to previous case reports, showed that the use of statins was significantly associated with elevated ALT at baseline. Among 53 case reports of liver injury associated with intake of GTE or tea-based products, 28 were consuming other medications concurrently (11, 12). Thus, the use of medications or preexisting conditions that require medication may exacerbate GTE-induced liver abnormal tests. In a small clinical trial involving 11 patients with multiple sclerosis (32), five of the six patients assigned to receive Polyphenon E (a mixed GTE formulation similar to ours) at a daily dose of 800 mg EGCG developed abnormal ALT compared to one in five control subjects who had a similarly abnormal ALT. The high incidence of liver enzyme elevation in these patients could be due to preexisting disease and/or concurrent use of medications.

The major limitation of this study is its generalizability. All study participants were healthy postmenopausal women and

virtually all were Caucasian. BMI range was limited to 19 to 40 kg/m^2 and women consuming 7 or more drinks of alcoholic beverages per week were excluded to avoid potential adverse effect of obesity and/or alcohol intake on liver enzyme in subjects in the GTE group, thus the generalizability may be limited. We do not know if the impact of GTE on liver enzyme elevation would be stronger in women who drink alcohol more frequently (e.g., >7 drinks per week). This study demonstrates that effect of GTE intake on liver enzyme elevation was present in both women with normal BMI (<25 kg/m^2) and never users of alcohol, suggesting there could be even higher impacts of high-dose GTE intake on liver enzyme elevation in the U.S. general population with high prevalence of obesity and high level of alcohol intake because obesity or heavy alcohol use may exacerbate the adverse effect of GTE on liver health. Moreover, the effects of specific ingredients in commercial green tea supplements on liver enzyme elevation cannot be ascertained from this study. The MGT study protocol did not call for further pathological evaluation of women who experienced ALT elevation to the level of severe liver injury. Future studies are warranted to elucidate the biological mechanisms for GTE on liver injury.

This randomized, double-blinded, placebo-controlled phase II clinical trial clearly demonstrates that high-dose of GTE intake for approximately 12 months associated with liver enzyme elevation in a small proportion of healthy postmenopausal women. The public should be informed about the potential risk of liver injury with a high, sustained dose of GTE as a dietary supplement, especially for those who are obese or have preexisting liver disease.

Disclosure of Potential Conflicts of Interest

L.M. Butler is an epidemiologist at Genentech, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: Z. Yu, C.S. Yang, M.S. Kurzer, J.-M. Yuan

Development of methodology: M.S. Kurzer, J.-M. Yuan

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H. Samavat, A.M. Dostal, C.J. Torkelson, M.S. Kurzer
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Z. Yu, R. Wang, L.M. Butler, T.W. Kensler, A.H. Wu, J.-M. Yuan

Writing, review, and/or revision of the manuscript: Z. Yu, H. Samavat, A.M. Dostal, C.J. Torkelson, C.S. Yang, L.M. Butler, T.W. Kensler, A.H. Wu, M.S. Kurzer, J.-M. Yuan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Wang

Study supervision: M.S. Kurzer, J.-M. Yuan

References

- Graham HN. Green tea composition, consumption, and polyphenol chemistry. *Prev Med* 1992;21:334–50.
- Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H. Cancer prevention by tea: evidence from laboratory studies. *Pharmacol Res* 2011;64:113–22.
- Huang YQ, Lu X, Min H, Wu QQ, Shi XT, Bian KQ, et al. Green tea and liver cancer risk: a meta-analysis of prospective cohort studies in Asian populations. *Nutrition* 2016;32:3–8.
- Ni CX, Gong H, Liu Y, Qi Y, Jiang CL, Zhang JP. Green tea consumption and the risk of liver cancer: a meta-analysis. *Nutr Cancer* 2017;69:211–20.
- Yuan JM. Cancer prevention by green tea: evidence from epidemiologic studies. *Am J Clin Nutr* 2013;98:1676s–81s.
- Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. *JAMA* 2006;296:1255–65.
- Yang CS, Zhang J, Zhang L, Huang J, Wang Y. Mechanisms of body weight reduction and metabolic syndrome alleviation by tea. *Mol Nutr Food Res* 2016;60:160–74.
- Yang CS, Hong J. Prevention of chronic diseases by tea: possible mechanisms and human relevance. *Annu Rev Nutr* 2013;33:161–81.
- Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. *Food Chem Toxicol* 2010;48:409–16.
- Wang D, Wang Y, Wan X, Yang CS, Zhang J. Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway. *Toxicol Appl Pharmacol* 2015;283:65–74.
- Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. *Arch Toxicol* 2015;89:1175–91.
- Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. *Eur J Clin Pharmacol* 2009;65:331–41.
- Butler LM, Huang JY, Wang R, Lee MJ, Yang CS, Gao YT, et al. Urinary biomarkers of catechins and risk of hepatocellular carcinoma in the Shanghai Cohort Study. *Am J Epidemiol* 2015;181:397–405.
- Yuan JM, Gao YT, Yang CS, Yu MC. Urinary biomarkers of tea polyphenols and risk of colorectal cancer in the Shanghai Cohort Study. *Int J Cancer* 2007;120:1344–50.
- Dostal AM, Samavat H, Bedell S, Torkelson C, Wang R, Swenson K, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. *Food Chem Toxicol* 2015;83:26–35.
- Samavat H, Dostal AM, Wang R, Bedell S, Emory TH, Ursin G, et al. The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics. *Cancer Causes Control* 2015;26:1405–19.
- Bhagwat S, Haytowitz DB. USDA database for the flavonoid content of selected foods, Release 3.2. 2015. Available from: <http://www.ars.usda.gov/nutrientdata/flav>. [Accessed October 30, 2016].
- National Institute of Disease and Digestive and Kidney Disease. Severity grading in drug induced liver injury; 2016. Available from: <https://livertox.nih.gov/Severity.html>. [Accessed April 20, 2017].
- Smitha T, Kawab K, Ecklb V, Johnsonc J. Sales of herbal dietary supplements in US increased 7.5% in 2015 Consumers spent \$6.92 billion on herbal supplements in 2015, marking the 12th consecutive year of growth. *J Am Botanical Council* 2016;111:67–73.
- Galati G, Lin A, Sultan AM, O'Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. *Free Rad Biol Med* 2006;40:570–80.
- Wan C, Han R, Liu L, Zhang F, Li F, Xiang M, et al. Role of miR-155 in fluorooctane sulfonate-induced oxidative hepatic damage via the Nrf2-dependent pathway. *Toxicol Appl Pharmacol* 2016;295:85–93.
- Furukawa A, Oikawa S, Murata M, Hiraku Y, Kawanishi S. (-)-Epigallocatechin gallate causes oxidative damage to isolated and cellular DNA. *Biochem Pharmacol* 2003;66:1769–78.
- Kucera O, Mezera V, Moravcova A, Endlicher R, Lotkova H, Drahotova Z, et al. *In vitro* toxicity of epigallocatechin gallate in rat liver mitochondria and hepatocytes. *Oxidative Med Cell Longevity* 2015;2015:476180.
- Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. *Translat Res* 2014;164:312–22.
- Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. *Clin Liver Dis* 2016;20:205–14.
- Flores YN, Auslander A, Crespi MC, Rodriguez M, Zhang ZF, Durazo F, et al. Longitudinal association of obesity, metabolic syndrome and diabetes

Acknowledgments

The authors would like to acknowledge the study participants, the data collection team, and study administrative staff at the Human Nutrition Research Clinic, Department of Food Science and Nutrition, University of Minnesota; the Oncology Research Department of the Park Nicollet Institute (St. Louis Park, MN), and the Investigational Drug Services pharmacy of the University of Minnesota Medical Center, Fairview. We also thank Corban Laboratories/Eniva Nutraceuticals for providing the study supplement.

Grant Support

The Minnesota Green Tea Trial was supported by the U.S. National Cancer Institute (R01 CA127236; to M.S. Kurzer). This work was partially supported by the U.S. National Cancer Institute (UM1 CA182876, to J.-M. Yuan; R35 CA197222, to T.W. Kensler; T32CA132670, A.M. Dostal) and Department of Defense/US Army Medical Research (W81XWH-11-1-0013; to H. Samavat). Both the National Cancer Institute's Cancer Center Support Grants of the University of Minnesota Masonic Cancer Center (P30 CA077598) and the University of Pittsburgh Cancer Institute (P30 CA047904) partially supported this work.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 20, 2017; revised July 6, 2017; accepted July 28, 2017; published OnlineFirst August 1, 2017.

- with risk of elevated aminotransferase levels in a cohort of Mexican health workers. *J Dig Dis* 2016;17:304–12.
27. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol* 2011;9:524–30.
 28. Cardoso GA, Salgado JM, Cesar Mde C, Donado-Pestana CM. The effects of green tea consumption and resistance training on body composition and resting metabolic rate in overweight or obese women. *J Med Food* 2013; 16:120–7.
 29. Narotzki B, Reznick AZ, Navot-Mintzer D, Dagan B, Levy Y. Green tea and vitamin E enhance exercise-induced benefits in body composition, glucose homeostasis, and antioxidant status in elderly men and women. *J Am College Nutr* 2013;32:31–40.
 30. Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. *Cochrane Database Syst Rev* 2012;12:Cd008650.
 31. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardi-olipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. *World J Gastroenterol* 2014;20:14205–18.
 32. Lovera J, Ramos A, Devier D, Garrison V, Kovner B, Reza T, et al. Poly-phenon E, non-futile at neuroprotection in multiple sclerosis but unpre-dictably hepatotoxic: phase I single group and phase II randomized placebo-controlled studies. *J Neurol Sci* 2015;358:46–52.